Plasma ceruloplasmin as a biomarker for obesity: A proteomic approach

Clinical Biochemistry

Volumn 44, Issue 5-6, 2011, Pages 351-356

  Kim, Oh Yoen ^a,b   Shin, Min Jeong ^c   Moon, Jiyoung ^c   Chung, Ji Hyung ^a,b,d  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Korea University   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

Biomarker; Ceruloplasmin; Obesity; Proteomics; Two dimensional gel electrophoresis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CERULOPLASMIN; CHOLESTEROL; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3C; FIBRINOGEN; GELSOLIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CERULOPLASMIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OBESITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; RELIABILITY; TANDEM MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDATION PROCESS;

BIOLOGICAL MARKERS; CERULOPLASMIN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79952765244     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.01.014     Document Type: Article

References (38)

1. Mello M.M., Studdert D.M., Brennan T.A. Obesity-the new frontier of public health law. N Engl J Med 2006, 354:2601-2610.
2. Hossain P., Kawar B., El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med 2007, 356:213-215.
3. South Korea Ministry of Health and Social Affairs. The Forth Korea National Health & Nutrition Examination Survey (KNHANES III). Ministry of Health and Welfare: Seoul, South Korea. 2008.
4. Sonnett T.E., Levien T.L., Gates B.J., Robinson J.D., Campbell R.K. Diabetes mellitus, inflammation, obesity: proposed treatment pathways for current and future therapies. Ann Pharmacother 2010, 44:701-711.
5. Li H., Xie Z., Lin J., Song H., Wang Q., Wang K., et al. Transcriptomic and metabonomic profiling of obesity-prone and obesity-resistant rats under high fat diet. J Proteome Res 2008, 7:4775-4783.
6. Bouchard L., Rabasa-Lhoret R., Faraj M., Lavoie M.E., Mill J., Pérusse L., et al. Differential epigenomic and transcriptomic responses in subcutaneous adipose tissue between low and high responders to caloric restriction. Am J Clin Nutr 2010, 91:309-320.
7. Yudkin J.S., Stehouwer C.D., Emeis J.J., Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 1999, 19:972-978.
8. Wang Z., Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediat Inflamm 2010, 2010:535918.
9. Engstroem G., Hedblad B., Stavenow L., Lind P., Janzon L., Lindgärde F. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes 2003, 52:2097-2101.
10. Engstroem G., Stavenow L., Hedblad B., Lind P., Eriksson K.-F., Janzon L., et al. Inflammation-sensitive plasma proteins, diabetes, and mortalityand incidence of myocardial infarction and stroke: a population based study. Arterioscler Thromb Vasc Biol 2004, 24:1498-1502.
11. Lind P., Hedblad B., Stavenow L., Janzon L., Eriksson K.F., Lindgärde F. Influence of plasma fibrinogen levels on the incidence of myocardial infarction and death is modified by other inflammation-sensitive proteins: a long-term cohort study. Arterioscler Thromb Vasc Biol 2001, 21:452-458.
12. Engstroem G., Lind P., Hedblad B., Stavenow L., Janzon L., Lindgärde F. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation 2002, 105:2632-2637.
13. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy Am women. Circulation 2003, 107:391-397.
14. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
15. Li T.W., Zheng B.R., Huang Z.X., Lin Q., Zhao Lk, Liao Z.T., et al. Screening disease-associated proteins from sera of patients with rheumatoid arthritis: a comparative proteomic study. Chin Med J 2010, 123:537-543.
16. Rodland K.D. Proteomics and cancer diagnosis: the potential of mass spectrometry. Clin Biochem 2004, 37:579-583.
17. Shevchenko A., Wilm M., Vorm O., Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996, 68:850-858.
18. Choi B.K., Cho Y.M., Bae S.H., Zoubaulis C.C., Paik Y.K. Single-step perfusion chromatography with a throughput potential for enhanced peptide detection by matrix-assisted laser desorption/ ionization-mass spectrometry. Proteomics 2003, 3:1955-1961.
19. Rydén L. Ceruloplasmin. Copper proteins and copper enzymes. Volume III 1984, 37-100. CRC Press, Boca Raton, FL. R. Lontie (Ed.).
20. Fox P.L., Mukhopadhyay C., Ehrenwald E. Structure, oxidant activity, and cardiovascular mechanisms of human ceruloplasmin. Life Sci 1995, 56:1749-1758.
21. Saenko E.L., Yaropolov A.I., Harris E.D. Biological functions of ceruloplasmin expressed through copper-binding sites and a cellular receptor. J Trace Elem Exp Med 1994, 7:69-88.
22. Shukla N., Maher J., Masters J., Angelini G.D., Jeremy J.Y. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor. Atherosclerosis 2006, 187:238-250.
23. Fox P.L., Mazumder B., Ehrenwald E., Mukhopadhyay C.K. Caeruloplasmin and cardiovascular disease. Free Radic Biol Med 2000, 28:1735-1744.
24. Memisoǧullari R., Bakan E. Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with Type 2 diabetes mellitus. J Diab Complic 2004, 18:193-197.
25. Daimon M., Susa S., Yamatani K., Manaka H., Hama K., Kimura M. Hyperglycemia is a factor for an increase in serum ceruloplasmin in type 2 diabetes. Diab Care 1998, 21:1525-1528.
26. Taysi S., Polat F., Gul M., Sari R.A., Bakan E. Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis. Rheumatol Int 2002, 21:200-204.
27. Cunningham J., Leffell M., Mearkle P., Harmatz P. Elevated plasma ceruloplasmin in insulin-dependent diabetes mellitus: evidence for increased oxidative stress as a variable complication. Metabolism 1995, 44:996-999.
28. Kannel W.B., Wilson P.W., Nam B.H., D'Agostino R.B. Risk stratification of obesity as a coronary risk factor. Am J Cardiol 2002, 90:697-700.
29. Jonsson S., Hedblad B., Engstroem G., Nilsson P., Berglund G., Janzon L. Influence of obesity on cardiovascular risk. Twenty-three-year follow-up of 22, 025 men from an urban Swedish population. Int J Obes 2002, 26:1046-1053.
30. Rao S.V., Donahue M., Pi-Sunyer F.X., Fuster V. Obesity as a risk factor in coronary artery disease. Am Heart J 2001, 142:1102-1107.
31. Ford E.S. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diab Car 1999, 22:1971-1977.
32. Festa A., D'Agostino R., Williams K., Karter A.J., Mayer-Davis E.J., Tracy R.P., et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes 2001, 25:1407-1415.
33. Panich V., Migliori M., De Pietro S., Taccola D., Andreini B., et al. The link of biocompatibility to cytokine production. Kidney Int 2000, 58:S96-S103.
34. Klebanoff S.J. Bactericidal effect of Fe2+, ceruloplasmin, and phosphate. Arch Biochem Biophys 1999, 295:302-308.
35. Ziakas A., Gavrilidis S., Souliou E., Giannoglou G., Stiliadis I., Karvounis H., et al. Ceruloplasmin is a better predictor of the long-term prognosis compared with fibrinogen, CRP, and IL-6 in patients with severe unstable angina. Angiology 2009, 60:50-59.
36. Fox P.L., Mazumder B., Ehrenwald E., Mukhopadhyay C.K. Cerloplasmin and cardiovascular disease. Free Rad Biol Med 2000, 28:1735-1744.
37. Das U.N. Is obesity an inflammatory condition?. Nutrition 2001, 17:953-966.
38. Duncan B.B., Schmidt M.I., Chambless L.E., Folsom A.R., Carpenter M., Heiss G. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults: the ARIC study. Obes Res 2000, 8:279-286.